Drug developers have long been under pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and resulting generic competition. Current weak economic conditions have exacerbated these challenges with sweeping R&D staff and budget reductions. In order to remain competitive, drug makers must now do more with less.
Technology transfer, particularly of new biotechnologies that offer novel means to address unmet medical needs, offers a way to cost effectively address these challenges. And for technology developers, the dynamics of the drug development market present an opportunity to monetize their inventions. A new executive market research report from Business Insights, Building Biotech Technology Transfer Opportunities, brings these forces into sharp focus using detailed case studies, proprietary market data, and expert strategic guidance. For details on this just-published report, including a full table of contents and sample pages, CLICK HERE.